1-cyclopentylpyrrolidine | 18707-33-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-cyclopentylpyrrolidine
• 英文别名: N-cyclopentylpyrrolidine；1-cyclopentyl-pyrrolidine；1-Cyclopentyl-pyrrolidin；N-Cyclopentyl-pyrrolidin
• CAS: 18707-33-0
• 化学式: C₉H₁₇N
• 分子量: 139.241
• InChiKey: XLSWEOGDHPRDKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-cyclopentylpyrrolidine 生成 N-(F-cyclopentyl)-F-pyrrolidine
  参考文献：
  名称：

  ONO, TAIZO;INOUE, YOSHIHISA;ARAKAWA, YOSHIO;NAITO, YOUICHIRO;FUKAYA, CHIK+, J. FLUOR. CHEM., 43,(1989) N, C. 67-85

  摘要：

  DOI：
• 作为产物：
  描述：

  环戊胺 在 四氢呋喃 、 aluminum oxide 、 氮 作用下， 生成 1-cyclopentylpyrrolidine
  参考文献：
  名称：

  Jurew et al., Zhurnal Obshchei Khimii, 1949, vol. 19, p. 1730,1732

  摘要：

  DOI：

文献信息

• [EN] 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE OU PIPÉRAZINE SUBSTITUÉS PAR 1,2,4-OXADIAZOLE COMME ANTAGONISTES DE SMO
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2010013037A1

  公开（公告）日：2010-02-04

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

  本发明涉及式(I)的化合物及其药学上可接受的盐、立体异构体或互变异构体，这些化合物是Sonic Hedgehog途径的抑制剂，特别是Smo拮抗剂。因此，本发明的化合物对治疗与异常Hedgehog途径激活相关的疾病有用，包括癌症，例如基底细胞癌、髓母细胞瘤、前列腺、胰腺、乳腺、结肠、骨骼和小细胞肺癌，以及上消化道的癌症。
• Photometric Characterization of the Reductive Amination Scope of the Imine Reductases from<i>Streptomyces tsukubaensis</i>and<i>Streptomyces ipomoeae</i>
  作者：Philipp Matzel、Lukas Krautschick、Matthias Höhne

  DOI：10.1002/cbic.201700257

  日期：2017.10.18

  reductive amination catalyzed by two promising imine reductases is established in a rapid photometric NADPH assay. Substrates ranging from aldehydes to ketones and from primary to secondary amines are accepted, thus giving access to various secondary and tertiary amine products.

  两种酶663种组合：在快速光度NADPH分析中确定了由两种有前途的亚胺还原酶催化的还原胺化中的底物范围。可以接受从醛到酮以及从伯胺到仲胺的各种底物，因此可以使用各种仲胺和叔胺产品。
• C(sp³)–H dehydrogenation and C(sp²)–H alkoxy carbonylation of inactivated cyclic amines towards functionalized N-heterocycles
  作者：Yan He、Fang Wang、Xinying Zhang、Xuesen Fan

  DOI：10.1039/c6cc10227a

  日期：——

  A novel and efficient synthesis of tetrahydropyridine-, dihydropyrrole-, and tetrahydroazepine-3-carboxylates via cascade reactions of cyclic amines with CO and alcohols is presented. To our knowledge, this should be the first example in which functionalized N-heterocycles were prepared through Pd-catalyzed C(sp3)-H dehydrogenation and C(sp2)-H carbonylation of cyclic amines.

  通过环胺与CO和醇的级联反应，提出了一种新颖而有效的四氢吡啶-，二氢吡咯-和四氢氮杂-3-羧酸酯的合成方法。据我们所知，这应该是第一个通过钯催化环胺的C（sp 3）-H脱氢和C（sp 2）-H羰基化制备N杂环的例子。
• [EN] PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS<br/>[FR] COMPOSÉS PYRIMIDINE EN TANT QU'INHIBITEURS DE LA TUBERCULOSE
  申请人：VERTEX PHARMA

  公开号：WO2011019405A1

  公开（公告）日：2011-02-17

  The present invention relates to compounds II useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the invention.

  本发明涉及化合物II，用作治疗结核病的抑制剂。该发明还提供了制备本发明化合物的方法。
• FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF
  申请人：SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

  公开号：US20160214994A1

  公开（公告）日：2016-07-28

  Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.

  揭示了一种融合嘧啶化合物，其中间体，制备方法以及其组成和应用。本发明提供了一种如式I所示的融合嘧啶化合物，该化合物的药用可接受盐，水合物，溶剂合物，以及光学异构体或前药。本发明还提供了应用式I所示的融合嘧啶化合物，药用可接受盐，水合物，溶剂合物，以及该化合物的光学异构体或前药在制备用于治疗和/或预防激酶相关疾病的药物中。本发明的融合嘧啶化合物I是一种高效的PI3激酶抑制剂，可用于制备用于预防和/或治疗细胞增殖性疾病，如癌症，感染，炎症和自身免疫疾病的药物。